Efficacy and safety of Everolimus and Exemestane in hormone-receptor positive (HR+) human-epidermal-growth-factor negative (HER2−) advanced breast cancer patients: New insights beyond clinical trials. The EVA studyMarina Elena Cazzaniga, Martina Dester, Mario Airoldi et al.|The Breast|2017Cited by 23
PANHER study: a 20-year treatment outcome analysis from a multicentre observational study of HER2-positive advanced breast cancer patients from the real-world settingLaura Pizzuti, Nicola Tinari, Laura Iezzi et al.|Therapeutic Advances in Medical Oncology|2021Cited by 10
Adjuvant capecitabine in triple negative breast cancer patients with residual disease after neoadjuvant treatment: real-world evidence from CaRe, a multicentric, observational studyFrancesca Sofia Di Lisa, Enzo Veltri, Eriseld Krasniqi et al.|Frontiers in Oncology|2023Cited by 9
Phosphorylated mTOR is associated to androgen receptor expression in early triple-negative breast cancerMirco Pistelli, Stefano Cascinu|Oncology Reports|2016Cited by 4
Everolimus (EVE) and exemestane (EXE) in patients with advanced breast cancer aged ≥ 65 years: new lessons for clinical practice from the EVA studyMarina Elena Cazzaniga, Valter Torri, Claudio Verusio et al.|Oncotarget|2018Cited by 4